TerminatedNot Applicable

Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders

Stopped: Not enough personnel

Canada300 participantsStarted 2022-04-15

Plain-language summary

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by neurological disorders and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of neurological disorders and associated cognitive changes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 18 years old and above * A score of ≥ 26 on the Montreal Cognitive Assessment (MoCA) * Able to provide informed consent * Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc are permitted). Exclusion Criteria: * Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control. * Evidence or history of significant neurological disorder (e.g. MS, PD, ALS, Dementia) * Use of prescription drugs known to influence ocular motor visual function, such as benzodiazepines, antipsychotics, and anticonvulsants. * Diagnosed with an active substance use disorder. * History of stroke. * Recent traumatic brain injury (within the last 6 months).

What they're measuring

Symbol Digit Modalities Test (SDMT) score, one time, at the day of enrolment.

Timeframe: Baseline

Trial details

NCT IDNCT05212727

SponsorInnodem Neurosciences

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-05-03